Mesna Injection

DRUG2 trials

Sponsors

Kite Pharma Inc., Tanta University

Conditions

Relapsed/Refractory Mantle Cell LymphomaTMJ Disorder

Phase 2

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

CompletedCTIS2023-506641-35-00

Kite Pharma Inc.Relapsed/Refractory Mantle Cell Lymphoma

Start: 2018-07-09End: 2025-06-17Target: 68Updated: 2025-03-10

Unknown Phase

MESNA Injection for TMJ Internal Derangement

CompletedNCT05882604

Tanta UniversityTMJ Disorder

Start: 2023-03-01End: 2024-03-10Updated: 2025-07-24